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ABSTRACT
Gestational diabetes mellitus (GDM) is the most common metabolic disorder in pregnancy and is
characterized by insulin resistance and decreased circulating glucagon-like peptide-1 (GLP-1). GDM
resolves rapidly after delivery implicating the placenta in the disease. This study examines the
biological functions that cause this pathology. The placenta releases syncytiotrophoblast-derived
extracellular vesicles (STB-EVs) into the maternal circulation, which is enhanced in GDM. Dipeptidyl
peptidase IV (DPPIV) is known to play a role in type 2 diabetes by breaking down GLP-1, which in
turn regulates glucose-dependent insulin secretion. STB-EVs from control and GDM women were
analysed. We show that normal human placenta releases DPPIV-positive STB-EVs and that they are
higher in uterine than paired peripheral blood, confirming placental origin. DPPIV-bound STB-EVs
from normal perfused placentae are dose dependently inhibited with vildagliptin. DPPIV-bound
STB-EVs from perfused placentae are able to breakdown GLP-1 in vitro. STB-EVs from GDM perfused
placentae show greater DPPIV activity. Importantly, DPPIV-bound STB-EVs increase eightfold in the
circulation of women with GDM. This is the first report of STB-EVs carrying a biologically active
molecule that has the potential to regulate maternal insulin secretion.
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Introduction
Gestational diabetes mellitus (GDM) is defined as glucose
intolerance resulting in hyperglycaemia, with an onset or
first recognition during pregnancy [1]. In 2015, approxi-
mately 17.8 million of births were affected by GDM [2],
with increasing prevalence directly linked to increasing
risk factors (e.g. obesity) in women of reproductive age [3].
GDM causes short- and long-term complications for
both mother and foetus. Maternal short-term risks
include caesarean section, post-partum haemorrhage
and/or preeclampsia, while the foetus is at increased
risks of macrosomia, birth trauma and a number of
metabolic imbalances including hypoglycaemia, conse-
quently increasing the risk of neonatal unit admission.
Moreover, women with GDM are at elevated risk for
developing impaired glucose tolerance and type 2 dia-
betes later in life. It is reported that up to 70% of
women with GDM develop type 2 diabetes within
5 years of delivery [4]. Children of women with GDM
also have increased lifetime risks of obesity and are
more likely to have impaired glucose tolerance and
diabetes in childhood and early adulthood [5,6].
Control pregnancy is characterized by a progressive
decrease in maternal insulin sensitivity, which facili-
tates glucose and lipid bioavailability for the foetus
[7,8]. As such, hyperinsulinemia with euglycemia is
observed in control pregnant women. GDM is charac-
terized by an exacerbation of this physiological insulin
resistance state associated with an insufficient insulin
secretion, ultimately resulting in hyperglycaemia [9].
The placenta is known to be centrally involved in
inducing the insulin resistance seen in this condition
and delivering the placenta rapidly improves GDM in
the short term, with simultaneous decreases in the
requirements for insulin and/or metformin and reduc-
tion of glucose levels to normal; yet the molecular
mechanisms by which the placenta impacts the mater-
nal insulin function remain unknown [10].
CONTACT Claire C. Bastie C.C.Bastie@warwick.ac.uk; Manu Vatish manu.vatish@obs-gyn.ox.ac.uk Division of Biomedical Sciences, Warwick
Medical School, Coventry, CV4 7AL/NDWRH, Level 3 Women’s Centre, Oxford, OX3 9DU, UK
*These authors contributed equally to this work.
Supplemental data for this article can be accessed here.
JOURNAL OF EXTRACELLULAR VESICLES
2019, VOL. 8, 1617000
https://doi.org/10.1080/20013078.2019.1617000
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited.
It is now well established that the syncytiotrophoblast
monolayer covering the placental chorionic villi releases
extracellular vesicles (EVs) into the maternal circulation
during pregnancy [11–13]. The placental origin of syncy-
tiotrophoblast-derived extracellular vesicles (STB-EVs) is
determined by the expression of the placental alkaline
phosphatase (PLAP) present in these EVs [14,15]. EVs
are classified as “small EV” (<200 nm; in this manuscript
SMALL STB-EV) and “medium/large EVs” (>200 nm;
MEDIUM/LARGE STB-EV) according to their size [16].
Importantly, STB-EV shedding from the placenta
increases as the pregnancy progresses, and positively
correlates with the physiological increase of insulin resis-
tance during pregnancy [13,17]. As such, STB-EVs might
allow communication between the placenta and the
maternal metabolism. Interestingly, circulating levels of
SMALL STB-EVs have been reported to be elevated in
GDM [18] and their role in other placenta-associated
disorders has been well described [19,20]. This strongly
supports the concept that STB-EVs are not simple debris,
but can interact with maternal cells.
Therefore, we hypothesized that STB-EVs might carry
factors impacting insulin secretion, a hallmark of preg-
nancy that is altered during the establishment of GDM.
For the reasons above, we investigated the presence and
biological function of Dipeptidyl peptidase IV (DPPIV).
DPPIV is a glycoprotein that rapidly cleaves the N-term-
inal dipeptides of incretin hormones (e.g. glucagon-like
peptide 1 (GLP-1)), which are known to increase insulin
secretion, and thus regulate glucose homeostasis. It is
known that DPPIV is elevated in type 2 diabetes mellitus
(T2DM) and DPPIV inhibitors are established as thera-
peutic agents for the treatment of T2DM [21]. The poten-
tial role of placentally derived DPPIV in GDM has not
previously been investigated. Our hypothesis was that
biologically active DPPIV is shed on STB-EVs and there
might be increased circulating levels in GDM.
Material and methods
Patients and samples
This project was approved by the Central Oxfordshire
Research Ethics Committee C (REFS 07/H0607/74 and
07/H0606/148). All participants gave written informed
consent. All participants were pregnant women sched-
uled for elective caesarean section at 39–40 weeks of
gestation. Oral glucose tolerance tests (OGTTs) were
performed at 26–28 weeks of gestation to diagnose
GDM. Criteria for GDM diagnosis were either a fasting
plasma glucose level ≥ .1 mmol/l and/or a glucose level
≥10.1 mmol/l at 1 h and/or ≥8.5 mmol/l at 2 h after a
75 g oral glucose load, and followed the cut-off values
established by guidelines from the National Institute of
Clinical Excellence [22]. Women with multiple preg-
nancies as well as patients with pre-pregnancy diabetes,
cardiovascular disease or pre-eclampsia were excluded.
The control group was defined as gestational age-
matched women without abnormal OGTT.
Placentae were collected in the operating theatre and
perfused within 10 min (n = 6 for both GDM and con-
trols). Blood samples were collected in citrated plasma
tubes (BD Vacutainer, Reading, UK). Peripheral blood
samples were taken from the left antecubital fossa, while
uterine vein blood samples were taken at caesarean sec-
tion prior to delivery of the foetus. Samples were centri-
fuged at 1500 ×g for 15 min to separate cells from
supernatant. The resulting platelet-poor plasma was
immediately used for flow cytometry analysis.
Additional placental biopsies were taken through the
maternal surface for protein expression analysis. Lysates
were obtained with HEPES buffer and a protease inhibitor
cocktail (SigmaAldrich, Gillingham,UK), and subjected to
a BCA protein assay (Sigma Aldrich, Gillingham, UK),
before storage at −20°C until analysis.
Immunohistochemistry
Placental tissues were fixed in 4% v/v formaldehyde,
embedded in paraffin blocks, cut in 10 μm thick sections
and placed on slides. Placental sections were deparaffi-
nized inHistoclear (Sigma Aldrich, Gillingham, UK), and
rehydrated in graded ethanol. For antigen retrieval, slides
were heated in 10 mM sodium citrate at pH 6 for 10 min,
and cooled down at room temperature (R/T). To limit
background staining, endogenous peroxidase activity was
blocked with 3% H2O2 in phosphate-buffered saline
(PBS). Slides were rinsed with distilled water prior to
blocking for non-specific antibody binding using 10%
Fetal Calf Serum (FCS) (Sigma Aldrich, Gillingham,
UK) in PBS-T (PBS with Tween-20) at R/T for 1 h.
Sections were incubated overnight at 4°C with 1%
FCS and 0.5 µg/ml anti-CD26 primary antibody
(Abcam, Cambridge, UK) or non-immune mouse IgG1
(Biolegend, London, UK) in PBS-T. Sections were washed
in PBS and incubated with anti-mouse IgG secondary
antibody (Life Technologies, Paisley, UK) in a humidify-
ing chamber at R/T for 1 h. Slides were washed with
0.01% PBS-T before being stained with DAB (Vector
Laboratories, Peterborough, UK). All slides were washed
in 0.01% PBS-T and distilled water before nuclei were
counter-stained with Hematoxylin (Thermo Fisher,
Paisley, UK) for 10min. Slides were dehydrated in graded
ethanol and Histoclear, mounted in Depex mounting
medium (Sigma Aldrich, Gillingham, UK) and examined
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using a Leica DMIRE 2 microscope. Images were taken
using Hamamatsu Orca digital camera andHCI software.
Isolation and characterization of STB-EVs
STB-EVs were obtained from a placental dual lobe perfu-
sion system as previously described [23]. Briefly, placen-
tae were perfused for 3 h and the maternal side perfusate
was collected and immediately centrifuged (Beckman
Coulter Avanti J-20XP centrifuge and Beckman Coulter
JS-5.3 swing out rotor) twice at 1500 ×g for 10 min at 4°C
to remove erythrocytes and large cellular debris.
Sequential centrifugations were performed to separate
STB-EVs according to their size. The supernatant was
collected and spun at 10,000 ×g (Beckman L80 ultracen-
trifuge and Sorvall TST28.39 swing out rotor) for 35 min
at 4°C to pellet syncytiotrophoblast medium/large extra-
cellular vesicles (MEDIUM/LARGE STB-EVs) (200 nm–
1 µm in diameter). MEDIUM/LARGE STB-EVs were re-
suspended in sterile PBS and the remaining supernatant
was passed through a 0.2 µm Stericup filter (Millipore,
Watford, UK) and spun at 150,000 ×g for 125 min at 4°C
(Beckman L80 ultracentrifuge and Sorvall TST28.39
swing out rotor) to pellet smaller size syncytiotrophoblast
extracellular vesicles (SMALL STB-EVs) (50–200 µm).
SMALL STB-EVs were re-suspended in sterile PBS.
Pellets containing MEDIUM/LARGE STB-EVs and
SMALL STB-EVs (from the 10K and 150K centrifuga-
tions, respectively) were assessed for protein concentra-
tion using a BCA protein assay kit (Sigma Aldrich,
Gillingham, UK). Particle size was characterized with
Nanoparticle Tracking Analysis (NTA; Nanosight
NS500, Malvern Instruments, Malvern, UK). MEDIUM/
LARGE STB-EVs were also characterized using a BD
LSRII flow cytometer (BD Biosciences, Wokingham,
UK) as previously described [23]. STB-EVs were charac-
terized by assessing the expression of STB-EVs-specific
protein markers (specifically PLAP) to confirm syncytio-
trophoblast origin and known markers of exosomes (e.g.
syntenin, Alix and CD9).
STB-EV size and particle characterization using NTA
STB-EVs diameter and concentration were measured
using a NanoSight NS500 (Malvern Instruments,
Malvern, UK) equipped with a sCMOS camera and the
nanoparticle tracking analysis software version 2.3, Build
0033 (Malvern Instruments, Malvern, UK). The instru-
mentwas calibrated prior to ourmeasurements, using silica
100nmmicrospheres (Polysciences,Warrington,UK). Size
distribution profiles and concentration of STB-EVs were
measured using a protocol previously described [23].
Immunoblotting
Placental lysates, MEDIUM/LARGE STB-EVs or
SMALL STB-EVs (30 µg) were separated on Mini-
Protean TGX NuPAGE gel cassettes (Bio-Rad, Oxford,
UK). Proteins were transferred onto a polyvinylidene
difluoride membrane (Bio-Rad Laboratories, Watford,
UK) in a Novex Semi-Dry Blotter (Life Technologies,
Paisley, UK). Membranes were blocked for 1 h at R/T in
5% (w/v) Blotto (Alpha Diagnostic, Eastleigh, UK) in
TBS-T (Tris-buffered saline solution with 0.1% Tween-
20) and incubated with primary antibodies: anti-
DPPIV/CD26 antibody (1 µg/ml) (R&D System,
Abingdon, UK) or anti-PLAP (1 µg/ml) (NDOG-2, In-
house) overnight, at 4°C. Membranes were washed three
times in TBS-T and incubated with horseradish perox-
idase (HRP)-conjugated secondary antibodies (Life
Technologies, Paisley, UK) in Blotto/0.1% TBS-T for
1 h at R/T. Membranes were washed three times in
TBS-T and antigen–antibody complexes were visualized
by chemiluminescence using an ECL kit (ECL Western
Blotting substrate, Thermo Scientific, Paisley, UK).
Magnetic bead depletion
Dynabeads M-280 Sheep Anti-Mouse IgG (Life
Technologies, Paisley, UK) conjugated to anti-DPPIV
(anti-CD26) antibody (Biolegend, London, UK) or anti-
PLAP antibody were prepared according to the manufac-
turer’s instructions. Dynabeads coated with anti-IgG1
antibody (Biolegend, London, USA) or anti-IgG2a anti-
body (Dako, Ely, UK) were used as controls. Briefly,
Dynabeads (50 µl) were washed in Ca2+ and Mg2+-free
PBS supplemented with 0.1% BSA and 2 mM EDTA at
pH 7.4, pelleted with a magnet, and re-suspended in the
same buffer. Beads were incubated with 6 µg of either
anti-PLAP, anti-DPPIV, anti-IgG1 or anti-IgG2a anti-
body on a rotating plate overnight, at 4°C. The beads
were aggregated using a magnet and supernatants were
discarded. MEDIUM/LARGE STB-EVs or SMALL STB-
EVs (25 µg for both) were incubated with 10 µl of anti-
human Fc receptor blocking reagent for 10 min at 4°C
prior to incubation with the beads overnight at 4°C for
depletion. Bound and unbound STB-EVs were separated
using a magnetic separator (Dynal, Oslo, Norway). Pellets
containing bound antigen-positive STB-EVs were immu-
noblotted. Supernatants (antigen-negative STB-EVs)
were analysed by NTA to calculate the percentage of
STB-EVs bound to the beads as follows:
%DPPIV or PLAP
¼ Total½   DPPIV or PLAP negative½ 
Total½   100
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Flow cytometry analysis
MEDIUM/LARGE STB-EVs analyses
MEDIUM/LARGE STB-EVs from 10K centrifugation
spin were characterized using a BD LSRII flow cytometer
(BD Biosciences, UK). TruCount tubes, containing a
known number of fluorescent beads suspended in
500 µl of filtered PBS, were used to establish the flow
rate. The background event rate was set at <1000 events/
min. MEDIUM/LARGE STB-EV samples were diluted in
filtered PBS to optimize an event rate of ∼300 events/s in
a final volume of 300 µl. Prior to staining, samples were
incubated with 10 µl of Fc receptor blocker (Miltenyi,
Woking, UK) for 10 min, at 4°C. Samples were then
labelled with anti-PLAP-PE, anti-DPPIV-Alexa Fluor
647 and Bio-maleimide-FITC (used as an MEDIUM/
LARGE STB-EV membrane marker (BODIPY FL N-(2-
aminoethyl)-maleimide); Thermo Fisher, Paisley, UK)
for 15 min at R/T. Isotype controls were matched to
their respective antibodies according to the concentra-
tion, fluorochrome type and heavy chain. Prior to data
acquisition, final volumes were adjusted to 300 µl with
PBS. A total of 100,000 events were collected for each
sample. EV gates were set at <1 µm using fluorescent
beads. The negative gates for staining were determined
using isotype control tests and set at 1%; both data ana-
lyses and figure generation were carried out using FlowJo
version 10.1 (Tree Star Inc, Ashland, OR, USA).
Plasma sample analyses
Plasma PLAP- and DPPIV-positive EVs were identified
using a four-colour flow cytometry protocol previously
described [24], but with additional modifications to
exclude contamination from other EV sources, by defin-
ing a “dump-channel” [25]. The “dump channel”
excluded the principal contaminants such as platelet
EVs (using anti-CD-41a-PE-Cy7), erythrocyte EVs
(using anti-CD235a-PE-Cy7) and EVs derived from all
other sources except STB or erythrocytes (using anti-
HLA Class I-PE-Cy7 and anti-HLA Class II-PE-Cy7).
Hundred microlitres of platelet-poor plasma was labelled
with these antibodies, together with anti-PLAP-PE and
anti-DPPIV-Alex-Fluor 647 for 15 min, at 4°C. Labelled
plasma samples were subsequently filtered using
Ultrafree-MC/Durapore-PVDF (Millipore, Watford,
UK) centrifugal filters (2 min, 800 ×g). MEDIUM/
LARGE STB-EVs were recovered from the top of the
filter unit in 100 µl of filtered PBS, and stained with
Bio-maleimide-FITC, which stains biological mem-
branes. Volumes were then adjusted to 500 µl with fil-
tered PBS, and each sample was analysed for 10 min by
flow cytometry. Filtrate (negative for Bio-maleimide) was
used to define control gates for Bio-maleimide and the
“Dump Channel” in order to separate the population
positive for Bio-maleimide and negative for contami-
nates. Events that fell into this gate (i.e. biological mem-
branes but not contaminants) were further analysed for
PLAP and DPPIV signal. To determine control gates for
anti-DPPIV-Alexa Fluor 647 and anti-PLAP-PE staining,
samples were treated with detergent Nonidet P-40 (Sigma
Aldrich, Gillingham, UK) (to destroy the vesicle lipid
membrane) and the gates were set at 1% cut-off. Both
data analyses and figure generation were carried out
using a FlowJo version 10.1.
DPPIV enzyme activity assay
DPPIV enzyme activity of the STB-EVs was determined
using a DPPIV-Glo Protease Assay (Promega,
Southampton, UK). Briefly, the luminescent DPPIV-
Glo Reagent was incubated at R/T for 30 min with either
clinical samples (STB-EVs isolated from perfused pla-
centae from both GDM and normal pregnancy), Tris-
BSA (blanks) or a purified DPPIV enzyme in Tris-BSA
as standard (Recombinant human CD26 protein,
Abcam, Cambridge, UK). Luminescence was measured
using a FLUOstar Omega apparatus (BMG Labtech,
Aylesbury, UK).
For the DPPIV enzymatic inhibition studies,
MEDIUM/LARGE STB-EVs and SMALL STB-EVs were
pre-treated with vildagliptin (DPPIV-specific inhibitor)
(Sigma Aldrich, Gillingham, UK) (0–100 nM) for 1 h,
and DPPIV residual enzymatic activity was determined.
STB-EV-boundDPPIVability to breakGLP-1wasmea-
sured using a GLP-1 active assay according tomanufacture
instructions (Cisbio, Codolet, France). MEDIUM/LARGE
STB-EV and SMALL STB-EVpools of threeGDMpatients
in series dilution were mixed with 1400 pg/ml of GLP-1,
respectively, and incubated with anti-Active GLP-1-Tb3
+Cryptate Antibody and with anti-Active GLP-1-d2 anti-
body overnight at RT. RecombinantDPPIV (Recombinant
human CD26 protein, Abcam, Cambridge, UK) was used
as positive control, and PBS was used as negative control.
HTRF measurement was performed using a CLARIOstar
apparatus (BMG Labtech, Aylesbury, UK).
Statistics
Results were statistically analysed using Prism 3.0
(GraphPad Software Inc, San Diego, CA, USA).
Comparisons of means between two groups were tested
using the independent two-sample Student’s t-test,
with statistical significance assigned when *p < 0.05.
Paired samples were compared with the Wilcoxon
matched-pairs signed rank test. Unpaired samples
were analysed using the Mann–Whitney test.
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Results
DPPIV is present in normal STB-EVs
STB-EVs were obtained after perfusion of placentae of
control/normal pregnancies. Transmission electron
microscopy analyses revealed particles with physical
characteristics consistent with medium/large EV
(MEDIUM/LARGE STB-EVs) and small EV (SMALL
STB-EVs) in pellets collected after 10K and 150K centri-
fugations of the perfusates, respectively (Figure 1(a,b)).
NTAs confirmed the heterogeneous size of the
MEDIUM/LARGE STB-EV population (approximately
0.2–1 µm) whilst the SMALL STB-EVs were more
homogenous particles with a smaller size range (approxi-
mately 50–200 nm) (Figure 1(c)).
The syncytiotrophoblast-specific marker PLAP
was expressed in both MEDIUM/LARGE STB-EVs
and SMALL STB-EVs, confirming the placental ori-
gin of these two particle populations (Figure 1(d));
and the expression of exosome-specific marker syn-
tenin was enriched in the SMALL STB-EVs fraction
(Figure 1(d)), with marginal expression in
MEDIUM/LARGE STB-EVs (Fig. S1). Expression of
known exosomal markers Alix and CD9 were also
found enriched in the SMALL STB-EVs fraction
(Fig. S1).
Figure 1. DPPIV is expressed in normal placentae, MEDIUM/LARGE STB-EVs and SMALL STB-EVs.
Transmission electronic microscopy of MEDIUM/LARGE STB-EVs (scale bar represents 1000 nm) (a) and SMALL STB-EVs (b) (scale bars represent
200 nm) isolated from normal placentae. (c) Representative Nanoparticle Tracking Analyses (NTA) size vs. distribution profiles of MEDIUM/LARGE
STB-EVs and SMALL STB-EVs from normal pregnancies. (d) Representative Western blot (n = 3) of DPPIV protein expression in whole placental
lysates, MEDIUM/LARGE STB-EVs and SMALL STB-EVs isolated from control term placentae. Recombinant human DPPIV protein (Rec. DPPIV) was
used as positive control. PLAP expression confirmed syncytiotrophoblast origin; expression of exosomal marker syntenin was enriched in SMALL
STB-EVs. Blots are representative of n = 3 separate experiments. (e) Control placental sections were subjected to immunohistochemical analysis for
DPPIV expression (left panel). DPPIV positivity is seen at the syncytiotrophoblast (arrow). As negative controls, placental sections were incubated
with anti-IgG1 antibody (right panel). Images are representative of n = 3 separate experiments. Scale bar sets at 200 µm.
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Our previous mass spectrometric analyses suggested
the presence of DPPIV, a glycoprotein that rapidly
cleaves and inhibits the incretin hormone GLP-1, in
MEDIUM/LARGE STB-EVs of normal pregnancies
[26]. We now confirmed DPPIV protein expression
in both MEDIUM/LARGE STB-EVs and SMALL
STB-EVs of normal pregnancies (Figure 1(d) upper
band) using specific immunoblotting. Consistent with
the literature, we detected DPPIV in the whole placen-
tal tissue, with a signal localized in the syncytiotropho-
blast layer (Figure 1(e)), demonstrating that DPPIV
was present at the site of STB-EVs production [26,27].
DPPIV is co-expressed with PLAP on MEDIUM/
LARGE STB-EVs and SMALL STB-EVs
Flow cytometry analysis was performed on MEDIUM/
LARGE STB-EVs isolated with 10K centrifugation of
maternal perfusate (Representative data shown in
Figure 2(a–e)). We first established an EV positive gate
(Figure 2(a)) using fluorescent microspheres of 1 μm.
Events that fell into this gate were subjected to further
analysis. Bio-maleimide positive gate was defined by
fluorescence minus one (FMO) (Figure 2(b)). PLAP
FMO and isotype control and DPPIV FMO and isotype
control were used to draw 1% cut-off gates for PLAP-
positive events (Figure 2(c)) and DPPIV-positive events
(Figure 2(d)), respectively. In Figure 2(e), the significant
co-expression of PLAP and DPPIV is demonstrated in
quadrant 2. We noted PLAP-positive and DPPIV-nega-
tive events in quadrant 3 as well as a very small (0.22%)
population of DPPIV-positive PLAP-negative events in
quadrant 1. Three separate analyses are shown in
Table 1. More than half of MEDIUM/LARGE STB-
EVs (56.5 ± 4.6%) were solely PLAP positive.
Importantly, 42 ± 4.5% of the MEDIUM/LARGE STB-
EVs were both PLAP and DPPIV positive, suggesting
that a large proportion of MEDIUM/LARGE STB-EVs
express both PLAP and DPPIV in control pregnancies.
In addition, total MEDIUM/LARGE STB-EVs were
incubated with either anti-DPPIV- or anti-PLAP-coated
magnetic beads and pulled out using a magnet. Particle
numbers in the DPPIV- or PLAP-depleted supernatants
were determined by NTA. Figure 2(f,g) revealed that
PLAP depletion decreased particle numbers by
60.61 ± 19.31%; and DPPIV depletion decreased particle
numbers by 35.74 ± 18.65%, essentially confirming the
fluorescence activated cell sorting (FACS) analyses.
Control experiments using IgG1- or IgG2a-coupled mag-
netic beads did not alter MEDIUM/LARGE STB-EVs
numbers (Figure 2(h)).
DPPIV or PLAP pull-out fractions were analysed by
immunoblotting to assess co-expression of DPPIV and
PLAP protein (Figure 2(i)). PLAP was found in the
DPPIV pull-out fractions and conversely, DPPIV was
found in PLAP pull-out fractions, confirming co-expres-
sion on both MEDIUM/LARGE STB-EVs population.
When MEDIUM/LARGE STB-EVs were incubated with
magnetic beads coated with PLAP, pull-out showed a
greater signal for DPPIV compared with the pull-out
from magnetic beads coated with DPPIV suggesting
that some DPPIV is intravesicular.
Lastly, essentially similar data were obtained for
SMALL STB-EVs. SMALL STB-EVs could not be ana-
lysed by flow cytometry, as their size is below the limit of
detection. Therefore, particle numbers in the DPPIV- or
PLAP-depleted SMALL STB-EVs supernatants were
determined by NTA. PLAP depletion decreased particle
numbers by 36.45 ± 23.01% and DPPIV depletion
decreased particle numbers by 18.94 ± 12.42% (Figure
3(a,b)). Control experiments did not alter SMALL STB-
EV numbers (Figure 3(c)). Additionally, we confirmed
that DPPIV and PLAP proteins were also found in the
same population of SMALL STB-EVs (Figure 3(d)).
DPPIV present in STB-EVs displays enzymatic
activity
Surface-bound DPPIV activity was next determined in
MEDIUM/LARGE STB-EVs and SMALL STB-EVs of
control pregnancies. Basal DPPIV activity was similar in
MEDIUM/LARGE STB-EVs and SMALL STB-EVs
(Figure 4(a,b)). Importantly, incubation with the
DPPIV-specific inhibitor vildagliptin inhibited DPPIV
activity in both MEDIUM/LARGE STB-EVs and
SMALL STB-EVs in a dose-dependent manner, demon-
strating that placental EVs expressed functional DPPIV.
Furthermore, we demonstrated that functional
DPPIV present on STB-EVs and SMALL STB-EVs
can degrade active GLP-1. Figure 5 shows that increas-
ing concentrations of MEDIUM/LARGE STB-EVs
(Figure 4(c)) and SMALL STB-EVs (Figure 4(d))
resulted in a dose-dependent decrease of active GLP-1.
DPPIV expressing STB-EVs in the maternal
circulation
The concentration of DPPIV-positive STB-EVs in uterine
vein (which drains the utero-placental unit) was compared
to peripheral venous blood in the same women (n = 5) in
order to confirm its release from the placenta. Briefly,
during routine caesarean section, blood samples were col-
lected from the uterine vein (after reflection of the bladder
and before uterine incision and prior to delivery of the
foetus) in order to obtain blood as soon as it left the utero-
placental unit. Concomitantly blood was also taken from
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Figure 2. DPPIV and PLAP co-expression in MEDIUM/LARGE STB-EVs.
Representative image of flow cytometry analysis of MEDIUM/LARGE STB-EV (n = 3) derived from dual placental lobe perfusion showing (a) forward scatter
(FSC) versus side scatter (SSC) dot plot of MEDIUM/LARGE STB-EVs. Fluorescent microspheres of 1 μm (Polysciences Inc., Warrington, PA, USA) were used
to establish a gate <1 μm. Events that fell into this gate were subject to further analysis. (b) Bio-maleimide (BioM) fluorochrome minus one (FMO) was
used to draw 1% cut-off gate for BioM-positive events. (c) PLAP FMO was used to draw 1% cut-off gate for PLAP-positive events. (d) DPPIV FMO was used
to draw 1% cut-off gate for DPPIV-positive events. (e) The co-expression of PLAP-PE and DPPIV-Alexa Fluor 647 on MEDIUM/LARGE STB-EVs (Quadrant 2).
(f) Representative Nanoparticle Tracking Analysis (NTA) size distribution profile of total MEDIUM/LARGE STB-EVs, MEDIUM/LARGE STB-EVs population
depleted of MEDIUM/LARGE STB-EVs expressing DPPIV and MEDIUM/LARGE STB-EVs expressing PLAP. (g) Percentage of particle number after PLAP or
DPPIV depletion. (h) Representative NTA size distribution profile of total MEDIUM/LARGE STB-EVs, MEDIUM/LARGE STB-EVs population depleted of
MEDIUM/LARGE STB-EVs expressing IgG2a and MEDIUM/LARGE STB-EVs population depleted of MEDIUM/LARGE STB-EVs expressing IgG1. Graphs are
representative of n = 3 experiments. (i) DPPIV and PLAP protein expression in total MEDIUM/LARGE STB-EVs (Total), in MEDIUM/LARGE STB-EVs population
pulled out with anti-DPPIV magnetic beads (DPPIV PO), in MEDIUM/LARGE STB-EVs population pulled out with anti-PLAP magnetic beads (PLAP PO), in
MEDIUM/LARGE STB-EVs population pulled out with anti-IgG2a magnetic beads (IgG2a PO) and in MEDIUM/LARGE STB-EVs population pulled out with
anti-IgG1 magnetic beads (IgG1 PO). Blot is representative of n = 3 experiments.
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the left ante-cubital fossa (peripheral vein) from the same
patient. Both samples were tested for presence of placental
EVs expressing both DPPIV and PLAP by flow cytometry.
As expected, concentrations of single PLAP-positive STB-
EVs were higher in uterine (25,210 ± 4842.20 events/ml)
than peripheral (6810 ± 1677.94 events/ml) venous plasma
of these pregnant women (Figure 5(a)).
Importantly, a similar gradient of PLAP and DPPIV
double-positivity (Figure 5(b)) was observed between
uterine (2340 ± 538.38 events/ml) and peripheral
(760 ± 197.69 events/ml) blood confirming placental
origin of these double-positive EVs. This gradient was
present in all samples. Representative flow cytometry
dot plot is available in the supplement (Fig. S2).
DPPIV activity is increased in STB-EVs of GDM
pregnancies
We compared DPPIV activity in placental EVs isolated
from normal and GDM perfused placentae (n = 6 for
both). The clinical characteristics of the patients from
whom STB-EVs were analysed are described in
Supplementary Table S1. MEDIUM/LARGE STB-EVs
from GDM placentae showed significant twofold
increase in DPPIV activity compared to MEDIUM/
LARGE STB-EVs from controls (Figure 6(a)). This
increased DPPIV activity was also seen in SMALL
STB-EVs from GDM placentae and was fivefold higher
than that found in controls (Figure 6(b)).
STB-EV-bound DPPIV expression is increased in
GDM peripheral plasma
Lastly, we investigated whether there were differences
in MEDIUM/LARGE STB-EVs expressing DPPIV in
Table 1. DPPIV is co-expressed with PLAP on MEDIUM/LARGE
STB-EVs.
Sample
PLAP+/DPPIV+
(%)
PLAP+/DPPIV−
(%)
1 40.6 57.1
2 50.3 48.2
3 35.0 64.1
Mean 42.0 56.5
SEM 4.5 4.6
Percentage of PLAP/DPPIV positivity and PLAP positivity in MEDIUM/LARGE
STB-EVs isolated from human placentae by dual-lobe placental perfusion
using flow cytometry in three independent biological samples. A total of
100,000 events recorded with data presented as mean ± SEM.
Figure 3. DPPIV and PLAP co-expression in SMALL STB-EVs.
(a) Representative Nanoparticle Tracking Analysis (NTA) size distribution profile of total SMALL STB-EVs, SMALL STB-EVs population depleted of
SMALL STB-EVs expressing DPPIV and SMALL STB-EVs expressing PLAP. (b) Percentage of particle number after PLAP or DPPIV depletion. (c) NTA
size distribution profile of total SMALL STB-EVs, SMALL STB-EVs population depleted of SMALL STB-EVs expressing IgG2a and SMALL STB-EVs
population depleted of SMALL STB-EVs expressing IgG1. Graphs are representative of n = 3 experiments. (d) DPPIV and PLAP protein expression in
total SMALL STB-EVs (Total), in SMALL STB-EVs population pulled out with anti-DPPIV magnetic beads (DPPIV PO), in SMALL STB-EVs population
pulled out with anti-PLAP (PLAP PO), in SMALL STB-EVs population pulled out with anti-IgG2a magnetic beads (IgG2a PO) and in SMALL STB-EVs
population pulled out with anti-IgG1 magnetic beads (IgG1 PO). Blot is representative of n = 3 experiments.
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the plasma of women with GDM. Double-positive
PLAP and DPPIV STB-EV levels in peripheral blood
were 8.58-fold increased in women with GDM,
compared to control women (Figure 7). Patient
characteristics are presented in Supplementary
Table S1.
Figure 4. DPPIV in MEDIUM/LARGE STB-EVs and SMALL STB-EVs is enzymatically functional.
(a) MEDIUM/LARGE STB-EVs and (b) SMALL STB-EVs from control women were incubated with 0, 1, 10 or 100 nM vildagliptin (inhibitor of DPPIV)
and DPPIV activity was measured. Percentage of residual DPPIV activity was calculated in (a) MEDIUM/LARGE STB-EVs and (b) SMALL STB-EVs.
Graphs are representative of n = 3 experiments performed independently in duplicates (*p < 0.05). (c) MEDIUM/LARGE STB-EVs and(d) SMALL STB-
EVs pools from three GDM women were diluted to 7, 1.4 or 0.07 mg/ml and incubated with 1400 pg/ml of standard GLP-1. Graphs show levels of
active GLP-1 measured after the incubation with MEDIUM/LARGE STB-EVs or SMALL STB-EVs. Recombinant DPPIV was used as positive control.
Graphs are representative of n = 3 experiments performed independently in duplicates (*p < 0.05).
Figure 5. DPPIV expressing STB-EVs are present in the circulation and are placentally derived.
Paired plasma samples were collected from the uterine and the peripheral vein of pregnant women. (a) Individual PLAP-positive event numbers
from matched peripheral and uterine vein plasma samples (n = 5 women; *p < 0.05). (b) Individual PLAP/DPPIV double-positive event numbers
from matched peripheral and uterine vein plasma samples (n = 5 women; *p < 0.05).
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Discussion
In this study, we investigated (1) the presence and
bioactivity of the well-established regulator of insulin
secretion DPPIV in STB-EVs during pregnancy and (2)
whether DPPIV concentration and/or activity was
changed in pregnancies complicated with GDM.
We found that the normal human placenta
releases STB-EVs that carry biologically active
DPPIV. This DPPIV was shown to have intrinsic
enzymatic activity and was also shown to degrade
active GLP-1. We further showed that GDM preg-
nancies are associated with a greater than eightfold
increase in DPPIV-positive STB-EVs concentration
in maternal plasma, compared to normal pregnan-
cies. Increased DPPIV biological activity was also
demonstrated in both MEDIUM/LARGE STB-EVs
and SMALL STB-EV from GDM placentae, com-
pared to controls.
EVs are now understood to play important roles in
mediating intercellular communication as well as regu-
lating biological signalling in target cells [19,28]. The
concentrations of STB-EVs released by the placenta
increase during normal pregnancy [13], which corre-
lates with the physiological establishment of insulin
resistance in normal pregnancies. In addition, the num-
ber of SMALL STB-EVs present in maternal plasma is
reported to be significantly increased in pregnancies
complicated with GDM [18]. Consistent with the hyper-
glycaemia observed in GDM, glucose concentrations
have been shown to increase exosome release from
trophoblast cells in vitro [29]. Thus, for the reasons
above we hypothesized that the composition of the
STB-EVs itself might be changed during GDM. We
focused on possible changes in molecules known to
impact insulin sensitivity or secretion, both of which
are altered in pregnancies complicated with GDM.
In 2000, our group performed a mass spectrometric
analysis of mechanically isolated MEDIUM/LARGE
STB-EVs in attempt to identify complexes that might
inhibit proliferation of endothelial cells [26]. One of the
molecules identified was DPPIV. We now demonstrate
that not only is DPPIV expressed in STB-EVs, with
increased concentration in GDM pregnancies, but also
that DPPIV is biologically active and can be inhibited
using a specific inhibitor. This differs from Liu et al. [30]
who reported no difference in DPPIV concentration
between normal and GDM pregnancies. However, whilst
Liu et al. measured the enzymatic activity of soluble
DPPIV, we directly measured DPPIV activity bound to
STB-EVs, which might explain the divergence. Another
possible explanation is that they used serum for analysis
in their study, which is not the most suitable medium for
Figure 6. DPPIV activity is increased in STB-EVs of GDM pregnancies.
(a) DPPIV concentration in MEDIUM/LARGE STB-EVs from GDM versus control isolated from placental perfusions (n = 6 for both groups; *p < 0.05).
(b) DPPIV concentration in SMALL STB-EVs from GDM versus control isolated from placental perfusions (n = 6 for both groups; *p < 0.05).
Figure 7. Placenta-derived DPPIV expression is increased in
GDM peripheral plasma.
Peripheral gestation-matched plasma samples were collected from
GDM (n = 8) and Control (n = 8) pregnant women. DPPIV and PLAP
double-positive events in 1 ml of plasma were identified by flow
cytometry. *P < 0.0157.
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EV analysis [31]. Jayabalan et al. [32] analysed plasma
exosomes from normal and GDM women at diagnosis
and showed that the overall DPPIV exosome levels were
downregulated, but this analysis did not target placental
EVs specifically nor did it analyse medium/large EVs.
DPPIV plays a major role in glucose metabolism by
regulating the secretion of insulin. In particular, DPPIV
rapidly degrades GLP-1 (a member of the incretin family),
consequently decreasing glucose-dependent insulin secre-
tion [21]. Decreased insulin secretion is also noted in
GDM pregnancies [10]. Reduced GLP-1 concentration
after meal uptake was described by Bonde et al. in both
normal and GDM pregnancies, but with significantly
higher decreases seen in GDM pregnancies [33].
Supporting this, we have shown that STB-EVs can
decrease active GLP-1. We also showed that DPPIV activ-
ity, although present in both normal and GDM pregnan-
cies, was increased in GDM pregnancies. This might
provide a possible explanation for the aforementioned
decline of GLP-1 observed in GDM. Additionally, the
reported greater numbers of SMALL STB-EVs in GDM
could also contribute to increased breakdown of GLP-1 in
GDM pregnancies. Interestingly, GLP-1 function rapidly
returns to normal in both GDM and normal pregnancies
after delivery [33], showing that the effect is remarkably
transient. Our finding is consistent with the hypothesis
that STB-EVs could reduce incretin bioavailability during
gestation by delivering active membrane-bound DPPIV,
which decreases postpartum as the release of STB-EVs
declines following placental delivery [34].
Whilst increased DPPIV in STB-EVs of GDM preg-
nancies might impact insulin sensitivity via the regulation
of GLP-1, other mechanisms could also be considered.
For example, a recent randomized and double-blind trial
demonstrated that the DPPIV inhibitor sitagliptin atte-
nuated insulin resistance and improved overall glycaemic
control in women with GDM by a purported reduction in
RBP4 (Retinol Binding Protein 4) levels [35]. However,
DPPIV levels were not determined in this study.
Finally, DPPIV is a multifunctional protein impli-
cated in the regulation of chemokine and cytokine
activities. GDM is also associated with an imbalance
between circulating pro- and anti-inflammatory cyto-
kines. Isolated SMALL STB-EV from GDM pregnan-
cies increases cytokine release from endothelial cells to
a greater extent than those of control pregnancies [36].
Therefore, it is possible that increased DPPIV activity
in GDM pregnancies might also affect the release or
the activity of circulating of pro- or anti-inflammatory
factors, which have been implicated in the dysregula-
tion of insulin signalling and the establishment of
insulin resistance. Further work to dissect this is
required.
Limitations of the study include the following: the
number of patients we have analysed is small, but the
isolation and characterization of these STB-EVs is time
intensive and complex. Our flow cytometry analysis (due
to the instrument’s limit of detection) focuses solely on
medium/large EVs. We accept that not all medium/large
EVs are analysed in this way – however, this is the same
for all samples. The data presented here are obtained
from term pregnancies and it would be important to
investigate the levels of STB-EVs DPPIV earlier in preg-
nancy, since the presence of STB-EV DPPIV might allow
earlier diagnosis if the elevation seen in GDM occurs
earlier in pregnancy. A larger study might allow us to
understand the contribution of maternal characteristics
(e.g. obesity, ethnicity) to the circulating DPPIV levels
and thus allow stratification of severity.
We have demonstrated that STB-EVs express DPPIV,
which is not only active but also present in higher quan-
tities in the maternal circulation. This raises the possibi-
lity of their use as a potential diagnostic tool. A larger
study would be required to further validate this approach
as a potential means of early GDM screening/diagnosis.
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